Elan Falls Most in Six Months on Skepticism on Strategy

Elan Corp. fell the most in almost seven months in New York trading on skepticism the Irish drugmaker will profitably reinvest the proceeds from selling the Tysabri multiple-sclerosis drug to Biogen Idec Inc.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.